Publications by Hege Elisabeth Giercksky Russnes
67 publications found
Original articles
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
J Immunother Cancer, 12 (1)
DOI 10.1136/jitc-2023-007990, PubMed 38242720
[Not Available]
Tidsskr Nor Laegeforen, 144 (1)
DOI 10.4045/tidsskr.23.0740, PubMed 38258713
A convolutional neural network STIFMap reveals associations between stromal stiffness and EMT in breast cancer
Nat Commun, 14 (1), 3561
DOI 10.1038/s41467-023-39085-1, PubMed 37322009
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
Nat Med, 28 (12), 2573-2583
DOI 10.1038/s41591-022-02126-1, PubMed 36482103
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
Acta Oncol, 61 (8), 955-962
DOI 10.1080/0284186X.2022.2098053, PubMed 35943168
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
JCO Precis Oncol, 6 (1), e2200015
DOI 10.1200/PO.22.00015, PubMed 35476549
Incidence of breast cancer subtypes in immigrant and non-immigrant women in Norway
Breast Cancer Res, 24 (1), 4
DOI 10.1186/s13058-021-01498-5, PubMed 35012613
Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
BMC Cancer, 21 (1), 1089
DOI 10.1186/s12885-021-08811-7, PubMed 34625038
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
Int J Cancer, 150 (1), 100-111
DOI 10.1002/ijc.33768, PubMed 34449877
Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppression
Mol Oncol, 16 (1), 88-103
DOI 10.1002/1878-0261.13047, PubMed 34165864
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer
JCI Insight, 6 (11)
DOI 10.1172/jci.insight.147617, PubMed 33886505
Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGFβ2
Nat Cancer, 2 (3), 327-339
DOI 10.1038/s43018-021-00179-8, PubMed 34993493
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J Transl Med, 18 (1), 269
DOI 10.1186/s12967-020-02421-w, PubMed 32620163
DNA copy number motifs are strong and independent predictors of survival in breast cancer
Commun Biol, 3 (1), 153
DOI 10.1038/s42003-020-0884-6, PubMed 32242091
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006
Microvessel density in breast cancer: the impact of field area on prognostic informativeness
J Clin Pathol, 72 (4), 304-310
DOI 10.1136/jclinpath-2018-205536, PubMed 30630872
Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers
Ann Oncol, 29 (11), 2223-2231
DOI 10.1093/annonc/mdy404, PubMed 30252041
Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors
Mol Oncol, 12 (11), 1838-1855
DOI 10.1002/1878-0261.12375, PubMed 30133130
Number of Risky Lifestyle Behaviors and Breast Cancer Risk
JNCI Cancer Spectr, 2 (3), pky030
DOI 10.1093/jncics/pky030, PubMed 31360858
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
Breast Cancer Res, 19 (1), 120
DOI 10.1186/s13058-017-0911-9, PubMed 29137653
Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Nat Commun, 8 (1), 1221
DOI 10.1038/s41467-017-01355-0, PubMed 29089486
AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth
Mol Cancer Ther, 17 (1), 254-263
DOI 10.1158/1535-7163.MCT-16-0868, PubMed 29054988
Alcohol, Physical Activity, Smoking, and Breast Cancer Subtypes in a Large, Nested Case-Control Study from the Norwegian Breast Cancer Screening Program
Cancer Epidemiol Biomarkers Prev, 26 (12), 1736-1744
DOI 10.1158/1055-9965.EPI-17-0611, PubMed 28877889
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
Cancer Discov, 7 (10), 1098-1115
DOI 10.1158/2159-8290.CD-17-0222, PubMed 28652380
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
Glycan-related gene expression signatures in breast cancer subtypes; relation to survival
Mol Oncol, 9 (4), 861-76
DOI 10.1016/j.molonc.2014.12.013, PubMed 25655580
Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors
Genes Chromosomes Cancer, 54 (4), 235-48
DOI 10.1002/gcc.22237, PubMed 25546585
GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images
Genome Biol, 15 (8), 442
DOI 10.1186/s13059-014-0442-y, PubMed 25168174
JARID1B is a luminal lineage-driving oncogene in breast cancer
Cancer Cell, 25 (6), 762-77
DOI 10.1016/j.ccr.2014.04.024, PubMed 24937458
Nuclear CSPP1 expression defined subtypes of basal-like breast cancer
Br J Cancer, 111 (2), 326-38
DOI 10.1038/bjc.2014.297, PubMed 24901235
Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status
BMC Cancer, 14, 211
DOI 10.1186/1471-2407-14-211, PubMed 24645668
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity
Cell Rep, 6 (3), 514-27
DOI 10.1016/j.celrep.2013.12.041, PubMed 24462293
The multitude of molecular analyses in cancer: the opening of Pandora’s box
Genome Biol, 15 (9), 447
DOI 10.1186/s13059-014-0447-6, PubMed 25316146
Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer
Cancer Res, 73 (21), 6424-34
DOI 10.1158/0008-5472.CAN-12-4573, PubMed 24030979
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer
Sci Transl Med, 5 (181), 181re1
DOI 10.1126/scitranslmed.3006112, PubMed 23596205
Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy
Acta Oncol, 52 (1), 91-101
DOI 10.3109/0284186X.2012.713508, PubMed 22934555
The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients
Breast Cancer Res, 13 (3), R61
DOI 10.1186/bcr2898, PubMed 21672237
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors
PLoS One, 6 (2), e16915
DOI 10.1371/journal.pone.0016915, PubMed 21364938
Paired distribution of molecular subtypes in bilateral breast carcinomas
Cancer Genet, 204 (2), 96-102
DOI 10.1016/j.cancergencyto.2010.09.012, PubMed 21504707
Allele-specific copy number analysis of tumors
Proc Natl Acad Sci U S A, 107 (39), 16910-5
DOI 10.1073/pnas.1009843107, PubMed 20837533
Genomic architecture characterizes tumor progression paths and fate in breast cancer patients
Sci Transl Med, 2 (38), 38ra47
DOI 10.1126/scitranslmed.3000611, PubMed 20592421
EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors
Sci Signal, 3 (124), ra43
DOI 10.1126/scisignal.2000876, PubMed 20516477
Complex landscapes of somatic rearrangement in human breast cancer genomes
Nature, 462 (7276), 1005-10
DOI 10.1038/nature08645, PubMed 20033038
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
Mol Oncol, 3 (5-6), 469-82
DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161
The estrogen receptor pathway in rhabdomyosarcoma: a role for estrogen receptor-beta in proliferation and response to the antiestrogen 4'OH-tamoxifen
Cancer Res, 68 (9), 3476-85
DOI 10.1158/0008-5472.CAN-07-3046, PubMed 18451176
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome
J Pathol, 214 (3), 357-67
DOI 10.1002/path.2278, PubMed 18044827
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer
Mol Oncol, 1 (2), 160-71
DOI 10.1016/j.molonc.2007.03.004, PubMed 19383292
Comparison of genetic changes in frozen biopsies and microdissected archival material from the same colorectal liver metastases
Diagn Mol Pathol, 6 (6), 318-25
DOI 10.1097/00019606-199712000-00003, PubMed 9559291
Review articles
Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models
Trends Pharmacol Sci, 43 (11), 973-985
DOI 10.1016/j.tips.2022.08.009, PubMed 36163057
Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters
Am J Pathol, 187 (10), 2152-2162
DOI 10.1016/j.ajpath.2017.04.022, PubMed 28733194
Principles and methods of integrative genomic analyses in cancer
Nat Rev Cancer, 14 (5), 299-313
DOI 10.1038/nrc3721, PubMed 24759209
Insight into the heterogeneity of breast cancer through next-generation sequencing
J Clin Invest, 121 (10), 3810-8
DOI 10.1172/JCI57088, PubMed 21965338
Triple-negative breast cancer: present challenges and new perspectives
Mol Oncol, 4 (3), 209-29
DOI 10.1016/j.molonc.2010.04.006, PubMed 20537966
[Microdissection--an important tool in molecular biology]
Tidsskr Nor Laegeforen, 120 (5), 598-600
PubMed 10833921
Other articles
Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature
Curr Oncol, 30 (11), 10007-10018
DOI 10.3390/curroncol30110727, PubMed 37999147
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 317
DOI 10.1186/s12967-022-03518-0, PubMed 35841045
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 225
DOI 10.1186/s12967-022-03432-5, PubMed 35568909
A national precision cancer medicine implementation initiative for Norway
Nat Med, 28 (5), 885-887
DOI 10.1038/s41591-022-01777-4, PubMed 35513529
Clinical trials in the era of precision cancer medicine - for the few or for the many?
Acta Oncol, 59 (7), 731-732
DOI 10.1080/0284186X.2020.1777582, PubMed 32579040
Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Nat Commun, 10 (1), 525
DOI 10.1038/s41467-019-08512-7, PubMed 30692535
Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Nat Commun, 9 (1), 5397
DOI 10.1038/s41467-018-07842-2, PubMed 30559362
eEF2K--a new target in breast cancers with combined inactivation of p53 and PTEN
EMBO Mol Med, 6 (12), 1512-4
DOI 10.15252/emmm.201404683, PubMed 25471453
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer (vol 1, pg 160, 2007)
Mol. Oncol., 4 (2), 169
DOI 10.1016/j.molonc.2010.01.003
Theses
Molecular classification of breast carcinomas
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 979, 1 b. (flere pag.)
BIBSYS 101481047, ISBN 978-82-8072-585-1